890812 | VSA 1
VSA‑1 – Semisynthetic Saponin Adjuvant
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
VSA 1
VSA‑1 – Semisynthetic Saponin Adjuvant
For in vitro and in vivo vaccination research only.
VSA-1 is a semisynthetic saponin adjuvant derived from Momordica saponin and developed for in vitro and in vivo vaccine research. Its design supports robust humoral and cellular immune responses with improved consistency and reduced toxicity.
In BALB/c mouse studies with the PCV13 pneumococcal glycoconjugate vaccine, VSA-1 was equivalent to QS-21 in inducing IgG and opsonophagocytic titers across multiple serotypes, including 3, 14, and 19A. With lower acute toxicity and scalable production, VSA-1 is well-suited for preclinical adjuvant evaluation.
Application
VSA-1 enhances immune responses in pneumococcal vaccine studies and demonstrates comparable performance to QS-21 and Alum in murine influenza models. Additionally, it boosts hemagglutination-inhibiting antibody titers, drives T-cell activation, and supports heterosubtypic protection. Its simplified synthesis reduces batch variability, making it a practical option for adjuvant screening and immunogenicity profiling.
Packaging
Avanti Research™ supplies VSA-1 as a white lyophilized powder in 1mg and 5mg packaging. Custom vial sizes and bulk pricing are available upon request. All batches undergo rigorous testing, ensuring high purity and reproducibility.
Our highest priority for the last 50+ years has been delivering consistent, high-performance immunological tools—Trust Avanti Research™ to provide the specialized products you need to drive groundbreaking biochemistry research.
C88H145NO39
C 57.41%, H 7.94%, N 0.76%, O 33.89%
CAS Registry Number is a Registered Trademark of the American Chemical Society
Powered by BiozJ. Med. Chem. 2019, 62, 21, 9976–9982 Publication Date:October 28, 2019 https://doi.org/10.1021/acs.jmedchem.9b01511
J. Med. Chem. 2022, 65, 21, 14589–14598 Publication Date:November 1, 2022 https://doi.org/10.1021/acs.jmedchem.2c01087
J. Med. Chem. 2020, 63, 6, 3290–3297 Publication Date:February 26, 2020 https://doi.org/10.1021/acs.jmedchem.9b02063
Vaccines (Basel) 2022 Aug 24;10(9):1383. https://doi.org/10.3390/vaccines10091383
Front Immunol. 2022 Dec 12:13:1079047. https://doi.org/10.3389/fimmu.2022.1079047
- Certificate of Analysis (Lot No. 890812P-5MG-A-010 and 7276PHA010)
- Certificate of Analysis (Lot No. 890812P-1MG-A-010 and 7276PGA010)
